Catalyst

Slingshot members are tracking this event:

Galena Biopharma Discontinues NeuVax (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation

Source Link:
http://investors.galenabiopharma.com/investors/press-releases/press-release-details/2016/Galena-Biopharma-Discontinues-NeuVax-nelipepimut-S-Phase-3-PRESENT-Interim-Analysis-based-on-Independent-Data-Monitoring-Committee-Recommendation/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GALE
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The letter is attached to the Form 8-K filed and available on the Company’s website. This planned safety and futility interim analysis was triggered after 70 qualifying disease free survival (DFS) events were reached, and a total of 71 events were reviewed by the IDMC.

http://investors.gal...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jun 29, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Neuvax, Nelipepimut-s, Idmc, Present Study
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.